BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19720924)

  • 1. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
    Cortes JE; Kantarjian HM; Goldberg SL; Powell BL; Giles FJ; Wetzler M; Akard L; Burke JM; Kerr R; Saleh M; Salvado A; McDougall K; Albitar M; Radich J;
    J Clin Oncol; 2009 Oct; 27(28):4754-9. PubMed ID: 19720924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
    Brümmendorf TH; Cortes JE; de Souza CA; Guilhot F; Duvillié L; Pavlov D; Gogat K; Countouriotis AM; Gambacorti-Passerini C
    Br J Haematol; 2015 Jan; 168(1):69-81. PubMed ID: 25196702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
    Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G
    Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
    Kantarjian HM; Shah NP; Cortes JE; Baccarani M; Agarwal MB; Undurraga MS; Wang J; Ipiña JJ; Kim DW; Ogura M; Pavlovsky C; Junghanss C; Milone JH; Nicolini FE; Robak T; Van Droogenbroeck J; Vellenga E; Bradley-Garelik MB; Zhu C; Hochhaus A
    Blood; 2012 Feb; 119(5):1123-9. PubMed ID: 22160483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
    Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
    N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
    Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
    Haematologica; 2010 Aug; 95(8):1415-9. PubMed ID: 20305139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
    Cortes JE; Baccarani M; Guilhot F; Druker BJ; Branford S; Kim DW; Pane F; Pasquini R; Goldberg SL; Kalaycio M; Moiraghi B; Rowe JM; Tothova E; De Souza C; Rudoltz M; Yu R; Krahnke T; Kantarjian HM; Radich JP; Hughes TP
    J Clin Oncol; 2010 Jan; 28(3):424-30. PubMed ID: 20008622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.
    Akard LP; Cortes JE; Albitar M; Goldberg SL; Warsi G; Wetzler M; Ericson SG; Radich JP
    Arch Pathol Lab Med; 2014 Sep; 138(9):1186-92. PubMed ID: 24308645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
    Quintás-Cardama A; Kantarjian H; Jones D; Shan J; Borthakur G; Thomas D; Kornblau S; O'Brien S; Cortes J
    Blood; 2009 Jun; 113(25):6315-21. PubMed ID: 19369233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
    Deininger MW; Kopecky KJ; Radich JP; Kamel-Reid S; Stock W; Paietta E; Emanuel PD; Tallman M; Wadleigh M; Larson RA; Lipton JH; Slovak ML; Appelbaum FR; Druker BJ
    Br J Haematol; 2014 Jan; 164(2):223-32. PubMed ID: 24383843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
    Kantarjian H; Shah NP; Hochhaus A; Cortes J; Shah S; Ayala M; Moiraghi B; Shen Z; Mayer J; Pasquini R; Nakamae H; Huguet F; Boqué C; Chuah C; Bleickardt E; Bradley-Garelik MB; Zhu C; Szatrowski T; Shapiro D; Baccarani M
    N Engl J Med; 2010 Jun; 362(24):2260-70. PubMed ID: 20525995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
    Sohn SK; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Yoon SS; Kim H; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Moon JH; Park SY
    Leuk Lymphoma; 2011 Jun; 52(6):1024-9. PubMed ID: 21463107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
    Kim SH; Menon H; Jootar S; Saikia T; Kwak JY; Sohn SK; Park JS; Jeong SH; Kim HJ; Kim YK; Oh SJ; Kim H; Zang DY; Chung JS; Shin HJ; Do YR; Kim JA; Kim DY; Choi CW; Park S; Park HL; Lee GY; Cho DJ; Shin JS; Kim DW
    Haematologica; 2014 Jul; 99(7):1191-6. PubMed ID: 24705186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
    Cervantes F; López-Garrido P; Montero MI; Jonte F; Martínez J; Hernández-Boluda JC; Calbacho M; Sureda A; Pérez-Rus G; Nieto JB; Pérez-López C; Román-Gómez J; González M; Pereira A; Colomer D
    Haematologica; 2010 Aug; 95(8):1317-24. PubMed ID: 20220063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
    Cortes JE; Kim DW; Kantarjian HM; Brümmendorf TH; Dyagil I; Griskevicius L; Malhotra H; Powell C; Gogat K; Countouriotis AM; Gambacorti-Passerini C
    J Clin Oncol; 2012 Oct; 30(28):3486-92. PubMed ID: 22949154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
    Baccarani M; Druker BJ; Branford S; Kim DW; Pane F; Mongay L; Mone M; Ortmann CE; Kantarjian HM; Radich JP; Hughes TP; Cortes JE; Guilhot F
    Int J Hematol; 2014; 99(5):616-24. PubMed ID: 24658916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
    Latagliata R; Ferrero D; Iurlo A; Cavazzini F; Castagnetti F; Abruzzese E; Fava C; Breccia M; Annunziata M; Stagno F; Tiribelli M; Binotto G; Mansueto G; Gozzini A; Russo S; Cavalli L; Montefusco E; Gugliotta G; Cedrone M; Russo Rossi A; Avanzini P; Pregno P; Mauro E; Spadea A; Celesti F; Giglio G; Isidori A; Crugnola M; Calistri E; Sorà F; Storti S; D'Addosio A; Rege-Cambrin G; Luciano L; Alimena G
    Drugs Aging; 2013 Aug; 30(8):629-37. PubMed ID: 23681399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
    Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
    N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
    Shah NP; Kim DW; Kantarjian H; Rousselot P; Llacer PE; Enrico A; Vela-Ojeda J; Silver RT; Khoury HJ; Müller MC; Lambert A; Matloub Y; Hochhaus A
    Haematologica; 2010 Feb; 95(2):232-40. PubMed ID: 20139391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.